STOCK TITAN

Aadi Bioscience Inc - AADI STOCK NEWS

Welcome to our dedicated news page for Aadi Bioscience (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aadi Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aadi Bioscience's position in the market.

Rhea-AI Summary
AADI - Aadi Bioscience, Inc. announces strong third-quarter financial results, including a 40% increase in FYARRO sales to $6.0 million. The company also highlights the progress of the PRECISION1 tumor-agnostic trial and the initiation of new Phase 2 studies for endometrial cancer and neuroendocrine tumors. Real-world NGS analysis reinforces the unmet need in TSC1 and TSC2 mutated cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.53%
Tags
-
Rhea-AI Summary
Aadi Bioscience, Inc. will participate in the Jefferies London Healthcare Conference on November 14-16, 2023. The company's President and CEO, Dave Lennon, Ph.D., will participate in a fireside chat on November 14, 2023, at 8:30 am GMT. The fireside chat will be webcast live on the Aadi Bioscience website and will be available for replay for approximately 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
-
Rhea-AI Summary
Aadi Bioscience, Inc. will host a conference call and webcast on November 8, 2023, to report third quarter 2023 financial results and provide an operational update. Participants can access the live webcast on the company's website and register in advance to participate via telephone. A replay of the conference call and webcast will be available on the company's website for at least 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.48%
Tags
conferences earnings
Rhea-AI Summary
Aadi Bioscience initiates Phase 2 trial for the treatment of endometrial cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience announces details of four poster presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
none
-
Rhea-AI Summary
Aadi Bioscience to present two posters at the North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
Rhea-AI Summary
Aadi Bioscience grants equity award to new CEO, Dave Lennon, with a nonstatutory stock option to purchase 490,000 shares of common stock at an exercise price of $4.30 per share. The option will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.48%
Tags
management
-
Rhea-AI Summary
Aadi Bioscience appoints Dr. Dave Lennon as President and CEO, bringing over 20 years of pharmaceutical experience and expertise in mTOR inhibitors. Leadership transition expected to accelerate growth and leverage nanoparticle technology in FYARRO. On track for interim analysis on 40 patients in PRECISION1 trial and trial initiations in endometrial and neuroendocrine cancers. Dr. Lennon's appointment expected to accelerate Aadi's growth as a precision oncology company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.16%
Tags
management
-
Rhea-AI Summary
Aadi Bioscience announces four abstracts selected for presentation at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
Rhea-AI Summary
Aadi Bioscience, Inc. (NASDAQ: AADI) announces participation in investor events: H.C. Wainwright 25th Annual Global Investment Conference and Morgan Stanley 21st Annual Global Healthcare Conference. CEO and CFO will present and participate in fireside chat respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
conferences
Aadi Bioscience Inc

Nasdaq:AADI

AADI Rankings

AADI Stock Data

43.95M
16.00M
12.45%
52.87%
3.84%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Blue Ash

About AADI

aadi bioscience inc. (aadi), is a rapidly growing biopharmaceutical company focused on the development and commercialization of precision medicines targeted to rare genomic alteration-driven cancers. aadi’s lead asset, fyarrotm (sirolimus albumin-bound nanoparticles for injectable suspension), is an mtor inhibitor targeting cancers driven by genetic alterations in mtor pathway genes. supported by leading healthcare investors, aadi is currently preparing for launch of fyarro in advanced malignant pecoma, a rare type of sarcoma with no previously approved therapies. aadi’s world class leadership team is comprised of industry veterans from top biotech companies who have proven track records of bringing blockbuster products to market. a science-first mindset and entrepreneurial spirit is in our genes. aadi’s vision to become a leading precision oncology company is further supported by ongoing work in tumor-agnostic biomarker-driven populations (e.g., pan tumor tsc1/2 alterations) and n